Retrospective analysis demonstrates significant clinical efficacy and tolerability of pola-R-CHP in DLBCL, highlighting its potential as a first-line treatment.
Key Points
To evaluate the clinical efficacy and tolerability of the pola-R-CHP regimen in newly diagnosed DLBCL patients.
Conducted a retrospective analysis of newly diagnosed DLBCL patients from 10 medical centers in Northeast China.
Primary treatment regimen was pola-R-CHP, with endpoints including overall response rate (ORR) and progression-free survival (PFS).
Data collected included patient demographics, disease characteristics, treatment outcomes, and adverse events.
85.42% overall response rate (ORR) in 48 enrolled patients.
1-year progression-free survival (PFS) rate of 87.50% and overall survival (OS) rate of 95.83%.
No significant difference in PFS or OS between patients with and without bulky disease.